Nestlé Invests in Food for Alzheimer’s Patients
To further its mission of becoming the world’s leading nutrition, health and wellness company, Nestlé has purchased a stake in a U.S. firm that manufactures specially formulated medical food for those suffering from Alzheimer’s disease.
In a statement posted on the Nestlé website, Luis Cantarell, President and CEO of Nestlé Health Science – a division of the company set up last year that aims to pioneer the growing area of personal health science nutrition, said that it was a step in the right direction for the company.
“Acquiring a stake in Accera is a strategic step forward in building up our brain health portfolio,” said Cantarell. “It fits well with our vision to develop a strong portfolio of science-based nutritional solutions to address chronic conditions.”
The exact stake in Accera has not yet been released but their name brand product, Axona, is used by up to 30,000 people in the United States already. Axona is intended for the clinical dietary management of mild to moderate Alzheimer’s disease according to Cantarell.
Axona provides an alternative energy source for those suffering from Alzheimer’s, whose brains lose the ability to use glucose throughout time, resulting in improved memory and cognitive functions in ongoing medical trials, Reuters reported.
Sean Flynn is a Junior Writer for The Daily Meal. Follow him on Twitter @BuffaloFlynn